TRT Monitoring Blood Test UK: Complete Guide

Medically reviewed content. Last updated: February 2026.

If you are on testosterone replacement therapy in the UK, regular blood monitoring is not a suggestion — it is a clinical necessity. A TRT monitoring blood test is how your clinician confirms your testosterone is in the right range, your haematocrit is not creeping into dangerous territory, your prostate markers remain stable, and your oestradiol is not quietly climbing behind the scenes.

Yet many men on TRT are under-monitored. Some receive an annual total testosterone check from their GP and nothing more. Others rely on a private clinic that tests only the markers included in their protocol, missing the wider metabolic picture. And a significant number of men who self-administer testosterone — whether prescribed or otherwise — monitor sporadically at best.

This guide covers the complete TRT monitoring blood test panel, the evidence-based schedule recommended by the British Society for Sexual Medicine (BSSM), the safety markers that matter most, and how to interpret your results with confidence.

Why Regular Monitoring on TRT Is Essential

Testosterone replacement therapy is a lifelong commitment for most men who start it. Unlike a course of antibiotics with a clear end date, TRT introduces exogenous testosterone into your body indefinitely — and your physiology adapts continuously. A TRT monitoring blood test serves three ongoing purposes that never diminish in importance.

1. Safety Surveillance

The most important reason to test is to catch problems before they cause harm. Testosterone stimulates erythropoiesis — red blood cell production — which means haematocrit rises in virtually every man on TRT. For most, it stabilises within a safe range. For a significant minority, it climbs toward 0.54, the threshold at which blood viscosity increases enough to raise the risk of venous thromboembolism, stroke, and major adverse cardiovascular events. A study published in the Journal of Urology found that polycythaemia developing during TRT independently predicts these events in the first year of therapy.

Without regular blood tests, you will not know your haematocrit is rising until symptoms appear — and by then, you may already be at elevated risk.

2. Dose Optimisation

The goal of TRT is not to push testosterone as high as possible. It is to reach stable levels in the mid-to-upper normal range (15–25 nmol/L) while minimising side effects. Blood tests reveal whether your dose is too low (persistent fatigue, low libido, trough levels below 12 nmol/L), too high (acne, mood disturbance, elevated haematocrit, oestradiol conversion), or appropriately dialled in.

Without objective data, dose adjustments become guesswork — and guesswork with a controlled substance carries real consequences.

3. Metabolic Tracking

TRT does not exist in a hormonal vacuum. It alters your lipid profile, can affect liver function, influences insulin sensitivity, and interacts with thyroid hormones through SHBG. A comprehensive monitoring panel tracks these downstream effects, giving you and your clinician a full picture of how TRT is affecting your body — not just your testosterone number.

The TRT Monitoring Panel: Every Marker Explained

A TRT monitoring blood test should go well beyond a simple total testosterone reading. The following table details every marker recommended by the BSSM and Endocrine Society guidelines, why each matters, the target range on treatment, and how frequently it should be checked.

The non-negotiable core — tested every time you monitor — is total testosterone, free testosterone, SHBG, oestradiol, and a full blood count (which includes haematocrit and haemoglobin). PSA, liver function, and lipids should be checked at least every 6–12 months, with HbA1c added to your annual review.

TRT Monitoring Schedule: When and How Often to Test

The BSSM practical guide recommends a structured monitoring schedule, front-loaded in the first year when your body is adapting to exogenous testosterone, then transitioning to annual reviews once stable. The table below aligns with BSSM and Endocrine Society recommendations, with the 6-week early check that most experienced TRT clinicians now include as standard.

Critical rule: If haematocrit exceeds 0.54 at any point, do not wait for your next scheduled test. The BSSM recommends immediate dose reduction or preparation change, with re-testing within 2–4 weeks. You should also be evaluated for sleep apnoea and chronic hypoxia, both of which compound erythrocytosis risk.

Timing Your Blood Draw by TRT Preparation

The form of testosterone you use determines exactly when your blood should be drawn. Getting this wrong can produce misleading results that lead to unnecessary dose changes.

• Testogel / Tostran (gels): Test 2–6 hours after applying the gel. Gels produce relatively stable levels, so a mid-morning draw captures a representative reading. Avoid drawing blood from the arm you applied gel to.
• Sustanon 250 (short-acting injection): Test at trough — the morning of your next injection, before injecting. This captures your lowest level. If your clinic also wants a peak reading, test 48–72 hours post-injection separately.
• Nebido (long-acting injection): Test mid-way between injections — approximately 5–6 weeks after the last injection for a standard 10–12 week interval. Trough readings just before the next injection should not fall below 10–12 nmol/L.
• Subcutaneous micro-dosing (e.g., twice-weekly Sustanon): Test on the morning of an injection day, before injecting. Levels should be relatively stable with frequent protocols.

Whichever preparation you use, keep the timing and laboratory consistent between draws. Different labs use different assays, making cross-lab comparison unreliable.

Safety Markers in Detail: Haematocrit and PSA

Two markers deserve particular attention in every TRT monitoring blood test. Both are manageable when caught early — and both can cause serious harm if left unmonitored.

Haematocrit: The Most Important Safety Marker

Testosterone stimulates the kidneys to produce erythropoietin (EPO), which drives red blood cell production. This is a normal physiological response — it is why men naturally have higher haematocrit than women. On TRT, this stimulation is amplified, and haematocrit rises in the majority of men, typically within the first 3–6 months.

The thresholds defined by major guidelines are:

• Below 0.50 (50%): Normal range. No action required.
• 0.50–0.52 (50–52%): Upper normal. Increase monitoring frequency. Ensure adequate hydration.
• 0.52–0.54 (52–54%): Elevated. Discuss dose reduction, preparation switch (gels cause less erythrocytosis than injections), and screen for sleep apnoea.
• Above 0.54 (54%): Requires intervention. The Endocrine Society, BSSM, and European Association of Urology all recommend dose reduction or cessation, evaluation for hypoxia and sleep apnoea, and potential therapeutic phlebotomy (blood removal).

Risk factors for TRT-related polycythaemia: injectable testosterone (especially Sustanon, which produces higher peaks), smoking, obstructive sleep apnoea, obesity, living at altitude, and older age. If you carry multiple risk factors, monitor haematocrit more frequently than the standard schedule.

PSA: Prostate Monitoring

The relationship between testosterone and prostate cancer has been extensively studied and the historical belief that TRT causes prostate cancer is not supported by current evidence. The 2023 BSSM guidelines and multiple large-scale studies found no increased risk of prostate cancer diagnosis, progression, or higher Gleason grades in men on TRT.

However, PSA monitoring remains a standard part of TRT surveillance, particularly for men over 40. What to look for:

• Expected PSA rise: A modest increase of 0.3–0.5 ng/mL in the first 6–12 months is normal. This typically plateaus.
• Red flag — rapid rise: A PSA increase exceeding 1.4 ng/mL within 12 months of starting TRT warrants urological referral.
• Red flag — absolute value: Any PSA above 4.0 ng/mL requires investigation, regardless of rate of change.
• Timing: PSA should not be measured within 48 hours of ejaculation, vigorous exercise, or a digital rectal examination, as all can temporarily elevate levels.

Oestradiol Management on TRT

Testosterone does not exist in isolation. It is converted to oestradiol by the aromatase enzyme, which is concentrated in adipose (fat) tissue. When your testosterone levels rise on TRT, more substrate becomes available for aromatisation — and oestradiol rises in proportion.

For most men, this increase is modest and well tolerated. But for others — particularly those carrying excess body fat — oestradiol can climb into symptomatic territory. This is why oestradiol belongs in every TRT monitoring blood test, not just occasional checks.

Symptoms of Elevated Oestradiol in Men

• Breast tenderness or gynecomastia (breast tissue growth)
• Water retention, bloating, and puffiness
• Emotional lability, irritability, or mood swings
• Reduced libido (paradoxically, despite adequate testosterone)
• Fat redistribution to hips and thighs
• Erectile dysfunction

Serum oestradiol above approximately 150 pmol/L commonly produces symptoms in men on TRT, though individual sensitivity varies. Some men tolerate higher levels without issues, while others are symptomatic at 120 pmol/L.

Managing Elevated Oestradiol

1. Reduce testosterone dose — less substrate means less aromatisation.
2. Switch from injections to gels — gels produce steadier testosterone levels with lower peaks, which reduces the aromatisation spike that occurs after injection.
3. Increase injection frequency — splitting the same total weekly dose into more frequent smaller doses (e.g., twice-weekly subcutaneous instead of fortnightly intramuscular) flattens peaks and reduces conversion.
4. Lose body fat — aromatase activity is directly proportional to adipose tissue mass. Even a 5–10% reduction in body fat can meaningfully lower oestradiol.
5. Aromatase inhibitors (AI) — drugs like anastrozole can be used under specialist supervision, but this is a last resort. AIs carry their own risks (bone density loss, joint pain, mood disturbance) and should not be used casually.

Monitor oestradiol at every TRT blood test. If levels are rising but still below 150 pmol/L and you have no symptoms, no intervention is needed — but watch the trend.

Signs Your TRT Dose Needs Adjusting

Blood test results and symptoms should always be interpreted together. Neither in isolation tells the full story. Here are the clinical patterns that indicate a dose change is warranted.

Signs Your Dose Is Too Low

• Persistent fatigue, low mood, or brain fog despite being on TRT for over 6 weeks
• Low libido or erectile difficulties that have not improved
• Trough total testosterone below 12 nmol/L
• Free testosterone at or below the lower reference range despite adequate total T (suggests high SHBG)
• Symptoms returning before your next injection (for Sustanon or Nebido users)

Signs Your Dose Is Too High

• Acne, oily skin, or hair thinning that appeared after starting TRT
• Sleep disturbance, irritability, or aggression
• Excessive sweating or night sweats
• Haematocrit above 0.52 and rising
• Oestradiol above 150 pmol/L with breast tenderness or water retention
• Peak testosterone consistently above 35 nmol/L

When Dose Adjustments Work Best

Make changes incrementally. Adjust by 10–20% at a time, then retest in 4–6 weeks. Avoid large dose jumps, as your body needs time to reach a new steady state before results are meaningful. If you are on injections and experiencing pronounced peaks and troughs, consider increasing frequency rather than reducing the total weekly dose — this often resolves symptoms without sacrificing efficacy.

How to Get a TRT Monitoring Blood Test in the UK

You have three main options for TRT blood monitoring in the UK:

1. Through your prescribing clinic or GP — most TRT clinics include periodic blood tests in their protocol. NHS GPs can request TRT monitoring panels, though the markers tested may be limited to total testosterone and FBC.
2. At-home venous blood test — a professional phlebotomist visits your home or workplace, draws a venous sample, and sends it to a UKAS-accredited laboratory. Results are typically available within 2 working days. This is the most convenient option and provides the most comprehensive panels.
3. Walk-in phlebotomy clinic — some providers offer appointments at partner clinics across the UK if you prefer an in-person setting.

Venous blood draws are strongly preferred over finger-prick capillary samples for hormone testing. Finger-prick samples can produce falsely elevated or inconsistent testosterone and SHBG readings due to haemolysis and smaller sample volumes. For reliable TRT monitoring, always opt for a venous draw.

Frequently Asked Questions

This article is for informational purposes only and does not constitute medical advice. Testosterone is a prescription-only medicine in the UK. Always consult your GP or TRT specialist before starting, stopping, or adjusting testosterone replacement therapy. Blood test results should be interpreted by a qualified healthcare professional in the context of your individual health history.